- Interim Director of Notre Dame California
- Interim Director of the Warren Family Research Center for Drug Discovery and Development, University of Notre Dame
- Associate Vice President for Research, University of Notre Dame
- Associate Dean, College of Science, University of Notre Dame
- Professor, University of Notre Dame
- Associate Professor, University of Notre Dame
- Assistant Professor, University of Notre Dame
- Merck Postdoctoral Associate, Stanford University
- Ph.D. in Chemistry, Rensselaer Polytechnic Institute
- B.S. in Chemistry, State University of New York, Oswego
- University of Notre Dame Faculty Award
- 5th Annual Negishi-Brown Lectures, Plenary Speaker
- Elected Fellow, American Association for the Advancement of Science
- Rev. Edmund P. Joyce Award for Excellence in Undergraduate Teaching
- Silveira Distinguished Lecturer, SUNY, Oswego
- Kaneb Teaching Award
- NSF CAREER Award
Our group is focused on the development of chemical and biological synthetic technologies for the production of natural products and natural product analogues and the study of their therapeutic potential for cancer and rare disease indications. In our lab, chemical synthesis tools such as methodology development and total synthesis are complemented by biological synthesis techniques such as bacterial fermentation, genetic and chemical manipulation, and heterologous expression. The power of synthesis enables access to the complex structures that are the foundation for a medicinal chemistry program.
Current projects include the development of chemical and biological methods for oxidative processing of putative biosynthetic intermediates towards the anti-cancer natural product, zampanolide and the anti-fungal, cyclopropane-containing polyketide, ambruticin. For several years, our lab has been studying the polyketide natural products, GEX1A and pladienolide, for their potential in rare diseases such as Niemann-Pick Type C and certain rare cancers.
Our lab also contributes to several collaborative rare disease programs within the Warren Center for Drug Discovery seeking therapeutic leads for rare indications such as NGly1 deficiency, Cori disease, and Behcet's disease.
- Larsen, E. M.; Chang, C.-F.; Sakata-Kato, T.; Arico, J. W.; Lombardo, V.; Wirth, D. F.; Taylor, R. E. Conformation-Guided Analogue Design Identifies Potential Antimalarial Compounds through Inhibition of Mitochondrial Respiration Org. Biomol. Chem. 2018, in press.
- Woods, L. M.; Arico, J. W.; Frein, J. D.; Sackett, D. L.; Taylor, R. E. "Synthesis and Biological Evaluation of 7-Deoxy-Epothilone Analogues." Int. J. Mol. Sci. 2017, 18, 648.
- Wagner, D. T.; Stevens, D. C.; Mehaffey, M. R.; Manion, H. R.; Taylor, R. E.; Brodbelt, J. S.; Keatinge-Clay, A. T. "alpha-Methylation follows condensation in the gephyronic acid modular polyketide synthase." Chem. Commun. 2016, 52, 8822.
- Chang, C.; Stefan, E.; Taylor, R. E. "Total Synthesis and Structural Reassignment of Lyngbyaloside C Highlighted by Intermolecular Ketene Esterification." Chem.-Eur. J. 2015, 21, 10681-10686.
- Stefan, E.; Taylor, R. E. "1,5-Hydride transfer protocol for the synthesis of beta-branched polyketide structural units." Tetrahedron Lett. 2015, 56, 3416.
- Naini, A.; Muthukumar, Y.; Raja, A.; Franke, R.; Harrier, I.; Smith,Amos B.,,III; Lee, D.; Taylor, R. E.; Sasse, F.; Kalesse, M. "The Synthesis and Biological Evaluation of Desepoxyisotedanolide and a Comparison with Desepoxytedanolide." Angew. Chem.-Int. Edit. 2015, 54, 6935-6939.
- Larsen, E. M.; Wilson, M. R.; Taylor, R. E. Conformation-activity relationships of polyketide natural products. Nat. Prod. Rep. 2015, 32, 1183-1206.